Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : U.S. will accept mixed doses of vaccines from international travelers

10/15/2021 | 07:02pm EST

WASHINGTON, Oct 15 (Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) said late on Friday that it will accept mixed-dose coronavirus vaccines from international travelers, a boost to travelers from Canada and other places.

The CDC said last week that https://www.reuters.com/world/us/us-will-accept-who-approved-covid-19-vaccines-international-visitors-2021-10-08 it would accept any vaccine authorized for use by U.S. regulators or the World Health Organization. "While CDC has not recommended mixing types of vaccine in a primary series, we recognize that this is increasingly common in other countries so should be accepted for the interpretation of vaccine records," a CDC spokeswoman said.

The White House said Friday the new vaccine requirements for foreign nationals traveling to the United States will begin Nov. 8 for visitors crossing at land borders as well as international air travelers.

Representative Brian Higgins, a New York Democrat representing a district along the Canadian border, had on Friday asked the CDC if it would accept the mixed vaccine doses noting "nearly four million Canadians, equivalent to 10% of their fully vaccinated population, have received mixed doses of the available mRNA COVID-19 vaccines – this includes the AstraZeneca vaccine."

The CDC said the vaccines approved by the Food and Drug Administration (FDA) for use, as well as those authorized by the WHO, will https://covid19.trackvaccines.org/agency/who be accepted for entry into the United States, including the AstraZeneca vaccine.

The CDC said "individuals who have any combination of two doses of an FDA approved/authorized or WHO emergency use listed COVID-19 two-dose series are considered fully vaccinated."

The CDC plans to answer other questions and release a contact tracing order for international air visitors by Oct. 25. (Reporting by David Shepardson; Editing by Leslie Adler and Aurora Ellis)


ę Reuters 2021
All news about ASTRAZENECA PLC
11:55aAstrazeneca To Scrap Plan For U.S. COVID Booster Study- Bloomberg News
RE
11/30Oxford University Says Existing COVID-19 Vaccines Will Protect Against Omicron
MT
11/30Officials offer vaccine reassurance; WHO advises against travel bans
RE
11/30FTSE 100 marks worst month in over a year on Omicron hit
RE
11/30AstraZeneca's Lynparza Secures FDA Priority Review for BRCA-Mutated HER2-Negative High-..
MT
11/30ASTRAZENECA : Lynparza Gets FDA Priority Review -- Update
DJ
11/30Lynparza granted Priority Review in the US for BRCA-mutated HER2-negative high-risk ea..
AQ
11/30Genetron, AstraZeneca to Collaborate to Develop Solid Tumor Tests in China
MT
11/30LONDON STOCK EXCHANGE : Doubts over vaccine efficiency send FTSE 100 down
11/30Presidential Taskforce On Covid-19 Endorses Pfizer-BioNTtech Vaccine for 12+ Year Olds
AQ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 919 M - -
Net income 2021 3 423 M - -
Net Debt 2021 25 253 M - -
P/E ratio 2021 37,4x
Yield 2021 2,56%
Capitalization 170 B 170 B -
EV / Sales 2021 5,45x
EV / Sales 2022 4,46x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 110,04 $
Average target price 137,51 $
Spread / Average Target 25,0%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC13.00%169 755
JOHNSON & JOHNSON-0.92%410 501
ROCHE HOLDING AG16.39%337 091
PFIZER, INC.45.97%301 579
NOVO NORDISK A/S65.17%243 741
ELI LILLY AND COMPANY46.91%224 871